Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06422923 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
A Phase 1 study of Epilepsy, Temporal Lobe, sponsored by Neurona Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 17
- Study locations
NCT06422923 is a Phase 1 study of Epilepsy, Temporal Lobe that is actively recruiting participants, run by Neurona Therapeutics. The registered enrollment target is 10 participants, below the 410-participant average among 4 other Epilepsy, Temporal Lobe trials with a reported enrollment target (98% lower). The trial reports 17 study locations across 11 states.
The verdict
NCT06422923, a Phase 1 study of Epilepsy, Temporal Lobe, is actively recruiting participants, sponsored by Neurona Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
Conditions Studied
Interventions
- BIOLOGICAL NRTX-1001
Study Locations (17)
California
- University of Southern California Keck Hospital - Los Angeles
- UC Irvine Medical Center - Orange
- Stanford University - Palo Alto
- University of California San Diego - San Diego
- University of California San Francisco - San Francisco
North Carolina
- Atrium Health - Charlotte
- Duke University Hospital - Durham
- Wake Forest Baptist Medical Center - Winston-Salem
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Illinois
- University of Chicago - Chicago
Iowa
- University of Iowa Health Care - Iowa City
New York
- SUNY Upstate Medical University - Syracuse
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2042-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06422923
The ClinicalTrials.gov registry entry for NCT06422923 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 410-participant average among 4 other Epilepsy, Temporal Lobe trials with a reported enrollment target (98% lower). The listed sponsor is Neurona Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy, Temporal Lobe appearing as the primary indexed condition, and to 1 intervention - of which NRTX-1001 is the first listed.
NCT06422923 reports 17 study locations spanning 11 distinct geographic areas - top geographies include California, North Carolina, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06422923 about?
NCT06422923 is a clinical study titled "A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)". This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
What is the current status of trial NCT06422923?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-11-14. Estimated completion is 2042-06-15.
What conditions does trial NCT06422923 study?
This clinical trial studies the following conditions: Epilepsy, Temporal Lobe.
What interventions are being tested in trial NCT06422923?
The interventions under investigation include: NRTX-1001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06422923?
This trial is sponsored by Neurona Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06422923 being conducted?
This trial has 17 study locations across Arkansas, California, Colorado, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Temporal Lobe
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.